Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.

被引：1
|
作者：
Heidel, F
Cortes, J
Ruecker, F
Kaufmann, M
Aulitzky, W
Letvak, L
Kindler, T
Huber, C
Dohner, H
Kantarjian, H
Fischer, T
机构：
[1] Univ Hosp Mainz, Mainz, Germany
[2] Univ Hosp Ulm, Ulm, Germany
[3] Robert Bosch Krankenhaus, Stuttgart, Germany
[4] Novartis Pharm Corp, E Hanover, NJ USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.1853.1853
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1853
引用
收藏
页码：527A / 527A
页数：1
相关论文
共 50 条
  • [31] Farnesyl transferase inhibitor (tipifarnib, zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-c) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Verstovsek, S
    Estrov, Z
    Giles, F
    Ravandi, F
    Wright, J
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 784A - 784A
  • [32] Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≤ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MOS).
    Faderl, S
    Gandhi, V
    Giles, F
    Estey, E
    Garcia-Manero, G
    O'Brien, S
    Wierda, W
    Kwari, M
    Craig, A
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 584S - 584S
  • [33] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    BLOOD, 2014, 124 (21)
  • [34] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
    Brunner, Andrew M.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Loo, Sun
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Kurtulus, Sema
    Makofske, Jessica
    Liao, Serena
    Mohammed, Anisa
    Sabatos-Peyton, Catherine A.
    Rinne, Mikael L.
    Borate, Uma
    Wei, Andrew H.
    BLOOD, 2020, 136
  • [35] Troxatyl™ plus topotecan, ara-C, or idarubicin in patients (pts) with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic-phase chronic myeloid leukemia (CML-BP):: A randomized Phase I/II study.
    Giles, FJ
    Faderl, S
    Thomas, DA
    Cortes, J
    Jeha, SS
    Garcia-Manero, G
    Douer, D
    Levine, AM
    Estey, EH
    Beran, M
    O'Brien, S
    Koller, C
    Andreeff, M
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 594A - 594A
  • [36] Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Tse, William
    Jia, Xuefei
    Elson, Paul
    Cooper, Brenda
    Ali-Osman, Francis
    Park, Jino
    Rao, Arati V.
    Rizzieri, David A.
    Wang, Eunice S.
    Cotta, Claudiu V.
    Kalaycio, Matt
    Sobecks, Ronald M.
    Rouphail, Basel
    Maciejewski, Jaroslaw P.
    Fensterl, Jaime
    Bailey, Laura
    Carew, Jennifer S.
    Foster, Bethany
    Rush, Mary Lynn
    Adams, Donna
    Griffiths, Elizabeth A.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [37] A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial
    Mussai, Francis
    De Santo, Carmela
    Cheng, Paul
    Thomas, Ian F.
    Ariti, Cono
    Upton, Laura
    Scarpa, Ugo
    Stavrou, Victoria
    Sydenham, Mia
    Burnett, Alan K.
    Knapper, Steven K.
    Mehta, Priyanka
    McMullin, Mary F.
    Copland, Mhairi
    Russell, Nigel H.
    Dennis, Mike
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (05) : 573 - 578
  • [38] PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Cortes, J.
    O'Connell, A.
    Shaik, M. N.
    Cesari, R.
    Abbattista, A.
    Woolfson, A.
    Pollyea, D.
    Savona, M.
    HAEMATOLOGICA, 2014, 99 : 33 - 33
  • [39] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [40] Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) ≥ 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML).
    Faderl, S
    Ravandi-Kashani, F
    Ferrajoli, A
    Estrov, Z
    Wierda, W
    Verstovsek, S
    Garcia-Manero, G
    Estey, EE
    Kwari, M
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 591S - 591S
12345